You are here
High HIV prevalence among IDU's in Libya
2 May, 2013
A recent study published in the April edition of Journal of Acquired Immune Deficiency Syndromes (JAIDS), has found a concentrated HIV epidemic among injecting drug users's (IDU's) in Libya, with 84% of IDU's admitted to the only drug-treatment centre in the country testing positive for the virus.
Europe austerity measures impacting access to healthcare
30 April, 2013
Austerity measures that have been placed in many European countries, as a response to the financial crisis, are putting a strain on public safety nets including healthcare systems.
American Supreme Court debates 'anti-prostitution' law
24 April, 2013
The 2003 law that obliges organisations funded by PEPFAR (President's Emergency Plan for AIDS Relief) to explicitly denounce sex work was debated on Monday at the Supreme Court, the highest court in the United States of America.
Performance-enhancing IDUs a missing group in HIV prevention
19 April, 2013
Research presented during the annual British HIV Association (BHIVA) conference in Manchester shows increases in the number of men injecting image- or performance-enhancing drugs.
Risky behaviour doesn't increase with PrEP in gay men
17 April, 2013
HIV-negative gay men in the US have been shown to not increase levels of risky sexual behaviour whilst on pre-exposure prophylaxis (PrEP), according to a study published in the JAIDS.
Quarter of pregnancy deaths in high prevalence settings due to HIV
10 April, 2013
A meta-analysis undertaken by the London School of Hygiene and Tropical Medicine has revealed that in high prevalence settings, pregnancy-related deaths due to HIV may be as high as one in four.
LGBT rights recognised by law in Honduras
5 April, 2013
The National Congress of Honduras has recently amended its Penal Code to establish a legal provision to protect people from discrimination on the grounds of sexual orientation and gender identity.
Novartis lose case to patent cancer drug Gilvec
2 April, 2013
A landmark case has been won in India, after Novartis lost their appeal to patent the anti-leukaemia drug, Gilvec. The Swiss pharmaceutical giant was originally refused the patent in January 2006, and has since been relentlessly pursuing legal action against the Indian authorities to overturn the decision.